Investigation | Screening | Baseline | Treatment | Follow-Up | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
 |  |  | 2 weeks | 2 weeks | 11 months | ||||||
Visit # | V0 | V1 | V2-10 | V11 | V12-20 | V21 | V22 | V23 | V24 | V25 | V26 |
informed consent | × |  |  |  |  |  |  |  |  |  |  |
demograph. data | × |  |  |  |  |  |  |  |  |  |  |
inclusion/exclusion criteria | × |  |  |  |  |  |  |  |  |  |  |
randomization |  | × |  |  |  |  |  |  |  |  |  |
ENT investigation/tinnitus localization |  | × |  |  |  |  |  |  |  |  |  |
audiogram/speech audiometry |  | × |  | × |  | × |  |  |  |  |  |
STI |  | × |  |  |  |  |  |  |  |  |  |
cTBS treatment SAC, TAC, PLC |  |  | × | × | × | × |  |  |  |  |  |
documentation of side effects |  |  | × | × | × | × |  |  |  |  |  |
TQ |  | × |  | × |  | x * | × | × | × | × | × |
VAS (distress, loudness) |  | × | × | × | × | × | × | × | × | × | × |
VAS (change) |  |  |  | × |  | × |  |  |  |  |  |
SCL-90R |  | × |  | × |  | × | × | × | × | × | × |
BDI |  | × |  | × |  | × | × | × | × | × | × |